CD274 and mature T-cell and NK-cell non-Hodgkin lymphoma: Geptanolimab was evaluated in a phase II clinical trial (NCT03502629) to determine its efficacy and safety in patients with R/R PTCL and to assess whether there was a correlation between PD-L1 expression and clinical prognosis.